Cell culture studies have established SH2 domain-containing protein tyrosine phosphatase-2 (SHP2) as an important factor in growth factor and cytokine-activated signaling pathways. However, the significance of SHP2 in the mammalian central nervous system (CNS) is not known since early embryonic lethality occurs in shp2 null mice. To bypass this embryonic lethality, transgenic animals containing a catalytically inactive mutant of SHP2 (SHP2-CS) under the control of a nestin intron II/thymidine kinase minimal promoter were generated. In the developing CNS of these animals, although high-level transgene expression was detected in the neuroepithelium, there was no obvious abnormality in progenitor cell proliferation or migration. In the adult brain, high-level transgene expression was detected in the subventricular zone, rostral migratory stream, dentate gyrus of hippocampus, and cerebellum. Because SHP2 function is likely important in cell survival pathways, we used a focal cerebral ischemia model to examined whether SHP2 is important during CNS injury. Ischemia-induced damage and neuronal death was found to be significantly greater in nestin-SHP2-CS mice than in wildtype littermates. These findings indicate that SHP2 is a required factor in signaling pathway(s) important for neuronal survival.-Aoki, Y., Huang, Z., Thomas, S. S., Bhide, P. G., Huang, I., Moskowitz, M. A., Reeves, S. A. Increased susceptibility to ischemiainduced brain damage in transgenic mice overexpressing a dominant negative form of SHP2. FASEB
SHP2 is a protein-tyrosine phosphatase containing a tandem array of SH2 domains at its NH 2 terminus and a catalytic domain at its carboxyl terminus. SHP2 has been shown to be an important factor in signaling pathways initiated through receptor tyrosine kinases (RTK) for epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin, fibroblast growth factor (FGF), and nerve growth factor (NGF; refs [1] [2] [3] [4] [5] . More recent studies have demonstrated a role for SHP2 in signaling pathways initiated through glycoprotein (gp)130, which is a common signal transducing subunit of the ciliary neurotrophic factor (CNTF) family of cytokine receptors (6) . Cultured cell experiments using SHP2 dominant negative mutants (1, (7) (8) (9) (10) (11) and antibody microinjection approaches (1, 12, 13) have established SHP2 as a required positive component in RTK and gp130 pathways, acting upstream of mitogen-activated protein kinase. In addition, SHP2 has been shown to be a negative regulator of STAT3 activation during CNTF signaling (6) . In contrast to these cell culture studies, the function of SHP2 during development is unclear, although SHP2 displays a high degree of homology with the product of the Drosophila corkscrew gene, which is required as a positive transducer downstream of the Torso receptor tyrosine kinase for normal embryo differentiation (14) . Microinjection of a SHP2 dominant negative mutant into Xenopus embryos has demonstrated that SHP2 is required for bFGF induced mesoderm induction and completion of gastrulation (3) . In agreement with these findings, targeted disruption of SHP2 in mice results in embryonic lethality during midgestation (15, 16) , where the animals exhibit gastrulation defects. Impaired bFGF and PDGF signaling is also observed in cultured embryonic stem cells from shp2 null embryos (15) . Thus, SHP2 appears to be a critical regulator of growth factor-activated signaling cascades in the developing embryo.
We have shown previously that SHP2 protein is present both in the proliferating neuroepithelium and in the postmitotic marginal zones of the mouse central nervous system (CNS) (17, 18) . However, in the adult CNS, SHP2 is present only in a subset of neurons and in astrocytes that have been made reactive due to ischemic injury (17) . We have also shown that SHP2 protein levels are increased in dying neurons after cerebral ischemia (17) . These data and the fact that in a variety of cell types SHP2 has a critical role in the activation of signal transduction cascades suggest that SHP2 may play an important role during CNS development and in mediating neuronal response to injury. In this report we investigated the role of SHP2 in CNS development and neuronal response to injury by using a transgenic mouse strategy that bypasses the early embryonic lethality that occurs in shp2 null mice.
MATERIALS AND METHODS

Construction of nestin-SHP2-CS-IRES-␤geo transgene and generation of transgenic mice
To generate the nestin-SHP2-CS-IRES-␤geo transgene, IRES␤geo was removed from pPGT. 1.8Ires ␤geo (kindly provided by Dr. Austin Smith) and inserted into the SmaI-SalI site of pBluescript II KSϩ (Stratagene, La Jolla, Calif.). The FLAGtagged dominant negative form of SHP2 containing a cysteine to serine substitution at amino acid 453 was constructed by inserting a BglII-HindIII fragment from pRK5-SHP2-CS (6) into Bglll-HindIII-digested PRK-NC1D (6). An EcoRI-HindIII fragment containing the FLAG-tagged SHP2-CS mutant was then inserted into a blunt-ended SpeI site of pBluescript II KS/IRES-␤geo. The rat nestin intron II and TK minimal promoter (19, 20) was removed from gIITK (kindly provided by Richard Josephson) by XhoI digestion and inserted into a blunt-ended NotI site of the pBluescript II KS/SHP2-CS-IRES␤geo. The nestin intron II and TK minimal promoter/CS-SHP2 junction was sequenced to confirm that the orientation of the insert was correct. The transgene was then removed from the vector by PacI digestion, which had been inserted as linkers at the 5Ј and 3Ј ends of the transgene. The resulting 8.9 kb fragment was gel purified, phenol-chloroform extracted, and purified by Elutip (Schleicher & Schuell, Keene, N.Y.), then used for injection of FVB/N mouse zygotes. Embryo donors were superovulated females. Injected embryos were implanted in the oviducts of day 1 pseudopregnant foster females.
Southern blot analysis
Ten micrograms of genomic DNA extracted from mouse tails was digested with EcoRV, separated on a 0.8% agarose gel, and transferred to a positively charged nylon membrane (NEN Lifescience, Boston, Mass.) by standard capillary blotting. A 1.1 Kb fragment from lacZ cDNA or a 1.7 kb fragment from SHP2 cDNA was used as a probe for hybridization. The blots were hybridized at 65°C overnight, rinsed with 2 ϫ SSC and 0.01% sodium dodecyl sulfate (SDS), and washed in 0.2 ϫ SSC and 0.01% SDS at 65°C for 30 min.
␤-Galactosidase staining of whole-mount embryos
For analysis of transgene expression, transgenic founder males or males born from founder females (F1) were crossed with wild-type FVB/N females, and E12 mice were analyzed by X-gal staining (21) . Briefly, embryos were fixed in 1% formaldehyde, 0.2% glutaraldehyde, 2 mM MgCl 2 , 5 mM EGTA, and 0.02% Nonidet P-40 for 60 min at room temperature, and then washed three times in phosphate-buffered saline (PBS) containing 0.02% Nonidet P-40. Finally, ␤-galactosidase activity was visualized by submerging the embryos in X-gal buffer [5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 , 0.01% Na-deoxycholate, 0.02% Nonidet P-40, and 0.5 mg/ml 5-bromo-4-chloro-3-indole-␤-D-galactoside (X-gal)] for overnight. After whole mount X-gal staining, brains were cut (50 -80 mm) using a Vibratome and mounted on slides.
␤-Galactosidase staining of adult brains and immunohistochemistry for cell type-specific markers Animals were anesthetized by an intraperitoneal (i.p.) injection of a mixture of ketamine (10 mg/kg body weight) and xylazine (10 mg/kg body weight) and killed by intracardiac perfusion with 3% paraformaldehyde in 0.1 M phosphate buffer, pH 7.35. The brains were removed, fixed for 5 h, and transferred to PBS. Brain sections were prepared on a Vibratome at 50 -80 mm thickness in the sagittal or coronal plane. For X-gal staining, floating sections were incubated in X-gal buffer for 5 h at 37°C. Sections were washed three times in PBS and either mounted on glass slides with DAPI mounting media (Vector Laboratories) or used for immunohistochemical staining. For immunohistochemistry, Vibratome sections were incubated with 3% normal donkey serum, 0.04% Tween-20 in PBS for 45 min at room temperature and then incubated with primary antibody for overnight at 4°C. The polyclonal anti-GFAP (Dako, Carpinteria, Calif.), monoclonal anti-NeuN (Chemicon, El Segundo, Calif.), and polyclonal anti-nestin (gift from Dr. R. J. D. Mckay, NINDS) antibodies were used to identify astrocytes, neurons, and neuroepithelial stem cells, respectively. Cy3-conjugated donkey anti-rabbit or goat anti-mouse IgG antibodies (Jackson Immunoresearch, West Grove, Pa.) were used as secondary antibodies. The sections were observed under a fluorescence microscope.
Immunoprecipitation and Western blotting
Frozen brains were homogenized in lysis buffer (50 mM Tris HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% Nonidet P-40, 0.25% Na-deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 2 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin, 50 g/ml phenylmethanesulfonyl fluoride). Tissue lysates were clarified using microcentrifugation at 10,000 g for 30 min at 4°C and immunoprecipitated with anti-FLAG epitope monoclonal antibody (M2, Kodak). Immunoprecipitates were fractionated on a 8% SDS-polyacrylamide gel and subjected to Western blotting analysis using anti-FLAG antibody (M2). Filters were stripped and probed with anti-SHP2 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.).
BrdU labeling of embryos for cell proliferation studies
Wild-type FVB/N females were mated with transgenic line 306 males. At embryonic day 12 (E12), pregnant females were injected with BrdU (bromodeoxyuridine, Sigma Chemical Co., St. Louis, Mo.) at a dose of 50 mg/g body weight (22) and killed 1 h later. Embryos were removed and their heads were fixed overnight in 70% ethanol. The remaining part of the body was used for genomic DNA isolation and genotyping by Southern blotting. Fixed heads were dehydrated in graded ethanol solutions and embedded in paraffin. Embedded heads were sectioned in the coronal plane at 4 m. BrdU immunohistochemistry was performed as described previously (22, 23) . Anti-BrdU monoclonal antibody (Becton Dickinson, Rutherford, N.J.) was used at a 1:75 dilution at room temperature for 30 min. Staining was developed using the Vecstatin ABC kit. Sections were counterstained with basic Fuchsin as described previously (22) .
Transient focal cerebral ischemia
Adult transgenic mice and wild-type littermates (4 -5 wk of age, 18 -24 g) were initially anesthetized with 2% halothane in 70% N 2 0 and 30% O 2 and then maintained on 1% halothane in a similar gaseous mixture. Core body temperature was monitored rectally (YSI, Yellow Springs, Ohio) and maintained normothermic (36.5°°C-37.5°C) by an electric blanket.
Focal cerebral ischemia was induced by the occlusion of the middle cerebral artery (MCA) using the intraluminal filament technique (24) . Briefly, The left common and external carotid arteries were isolated and ligated through a ventral midline incision. A microvascular clip (Zen temporary clip, Ohwa Tsusho, Tokyo, Japan) was temporarily placed on the internal carotid artery and the pterygopalatine artery. An 8 -0 nylon monofilament (Ethicon, Somerville, N.J.) coated with silicone was introduced into the internal carotid artery via the external carotid artery and then advanced 10 mm distal to the carotid bifurcation so as to occlude the MCA. The wound was sutured and the animals returned to their cages. Two hours postocclusion, the animals were briefly anesthetized as described above and the filament was withdrawn to initiate reperfusion.
Determination of infarct volume and infarct area
Six days after the MCA occlusion, animals were anesthetized by an i.p. injection of a mixture of ketamine and xylazine and killed by perfusion via an intracardiac route as described above. After perfusion, brains were immersed in the same fixative for overnight at 4°C. The brains were immersed in 15% sucrose overnight, then in 30% sucrose overnight, and frozen on dry ice. Coronal 20 mm sections were collected at 2 mm intervals and used for hematoxylin-eosin staining. The infarction area was measured using an image analysis system (M4, Imaging Research, St. Catherine's, Ontario, Canada) and infarction volume was calculated by summing the infarct volumes of sequential sections. To eliminate the effects of edema, infarct size was also calculated as a percentage of infarction by the formula: (contralateral hemisphere-ipsilateral nonischemic hemisphere)/contralateral hemisphere ϫ 100%, as described previously (25) .
Measurement of cerebral blood flow (CBF)
Successful occlusion of the middle cerebral artery was verified by laser Doppler flowmetry (Model PF 2B, Perimed, Stockholm, Sweden) and recorded on a MacLab/8 data acquisition system (AD Instruments, Milford, Mass.). Cortical CBF was recorded from a fiberoptic probe affixed to the skull (2 mm posterior and 6 mm lateral to bregma) in an area known to correspond to the ischemic core. Baseline CBF was measured before MCA occlusion and recorded continuously during and after the ischemic period. The resulting changes in CBF were expressed as a percentage relative to the baseline values.
An indicator fractionation technique using 14 C-iodoamphetamine (26, 27) was used to determine whether mutant and wild-type mice differed in the absolute value of their resting cerebral blood flow. Briefly, animals were anesthetized as described above. The right femoral artery and jugular vein were cannulated with PE-10 polyethylene tubing. After determining MABP and blood gases, arterial blood was withdrawn continuously from the femoral artery at a rate of 0.3 ml/min. One microcurie of N-isopropyl-[methyl 1,3-
14 C]-piodoamphetamine (American Radiolabeled Chemicals Inc., St. Louis, Mo.) dissolved in 0.1 ml saline was injected into the jugular vein as a bolus (Ͻ1 s). Twenty seconds after injection, the animal was decapitated and the blood withdrawal terminated simultaneously. The brain was removed and quickly frozen in isopentane solution, chilled with ice, and then dissected into right and left hemispheres. After adding scintigest (Fisher Scientific, Pittsburgh, Pa.) and incubating (50°C for 6 h), scintillation fluid and H 2 O 2 were added. Twelve hours after shaking, radioactivity in the brain and blood were measured by liquid scintillation spectrometry and CBF was calculated.
RESULTS
Generation of transgenic nestin-SHP2-CS mice
To clarify the role of SHP2 in the mouse CNS, we generated transgenic mice in which SHP2 function has selectively been removed from restricted populations of cells in the CNS. Specific ablation of SHP2 activity was accomplished by using a portion of the nestin intron II to direct expression of a dominant negative SHP2 mutant (SHP2-CS) to the neuroepithelium of the developing mouse and to a subset of neurons in the adult nervous system. Downstream of the SHP2-CS mutant, a bacterial lacZ-neomycin fusion gene (␤geo) was placed under the control of an internal ribosome entry site (IRES) to monitor transgene expression (Fig. 1) .
Transgene expression in E12 nestin-SHP2-CS mice
The expression pattern of the nestin-SHP2-CS transgene was analyzed in F1 (from male founders) and F2 (from female founders) offspring from two male (302 and 305) and five female (306, 307, 308, 309, and 310) transgenic lines. The nestin intron II has been shown previously to direct expression of a transgene to the neuroepithelium of the embryo, Figure 1 . Schematic presentation of the nestin-SHP2-CS construct used to generate transgenic mice. HSV TK, herpes simplex virus thymidine kinase minimal promoter; IRES, internal ribosomal entry site; ␤geo, ␤-galactosidase and neomycin resistant fusion gene.
which is detectable between E9.5 and E17.5 (19, 20) . Whole-mount X-gal staining of E12 mice from lines 305, 306, and 310 showed strong staining in the neuroepithelia of the forebrain, midbrain, hindbrain, and spinal cord. An example of this pattern of developmental expression from line 306 is shown in Fig. 2A --C and a summary of staining of all transgenic animal lines is shown in Fig. 2E . The overall staining was stronger in lines 306 and 310 than in line 305. Line 309 showed strong staining in the ventricular zone of the forebrain and midbrain, but weak staining in the hindbrain and none in the spinal cord. Line 308 showed weak staining only in the forebrain. Lines 302 and 307 did not show detectable transgene expression (data not shown). To demonstrate that the SHP2-CS mutant is cotranslated with ␤geo, we immunoprecipitated the FLAG epitope-tagged SHP2-CS mutant from total head lysates derived from nestin-SHP2-CS line 306 and wild-type E12 embryos. Probing the filters with either anti-FLAG or anti-SHP2 antibodies confirmed that the SHP2-CS mutant is cotranslated with ␤geo (Fig. 2F) .
Transgene expression in the adult brain
To examine regional and cell-type specific expression of the nestin-SHP2-CS transgene in the adult brain, we performed X-gal staining on sections of brains from 2 month-old F1 offspring from line 306 (Fig. 3A--F) . Staining was seen in the subventricular zone (SVZ), rostal migratory stream (RMS), dentate gyrus of the hippocampus, and cerebellum, which is in agreement with where nestin immunoreactivity has been reported previously (19, 20, 28 -31 ) (see Fig. 4A , B for an example of costaining for X-gal and nestin in the SVZ). Thus, the transgene appears to be localized to regions of the adult brain that are known to contain nestin-positive proliferating progenitor cells. In previous studies nestin immunoreactivity has not been detectable in the midbrain and the cerebral cortex, although some immunoreactivity has been seen in blood vessels (32) . Therefore, the nestin-SHP2-CS transgene also is expressed in cells not previously known to be nestin positive. A summary of transgene expression in all adult trans- genic lines is shown in Fig. 3F . Because line 306 showed the strongest level of transgene expression, this line was used for further analysis.
To determine whether the transgene expressing cells were neurons or glia, we performed immunohistochemistry on brain sections from line 306 using antibodies to nestin, NeuN and GFAP, which are markers for progenitor cells, neurons and astrocytes respectively (Fig. 4E) . None of the X-gal-labeled cells were colabeled for GFAP; however, some cells in the cerebral cortex, midbrain, and hippocampal pyramidal cell layer were colabeled for NeuN (see Fig. 4C,  D) . In summary, nestin-SHP2-CS transgene expression is directed to cells in the SVZ, RMS, dentate gyrus, and cerebellum. Some neurons in the cerebral cortex and midbrain and pyramidal cells in the hippocampus also express the transgene.
CNS development is normal in nestin-SHP2-CS mice
In the developing mouse, CNS postmitotic cells exit the proliferative neuroepithelium lining the ventricular cavities and migrate along radial glial fibers to reach the marginal zones where they differentiate and extend axonal processes. SHP2 may have a role in progenitor cell proliferation as well as neuronal migration and differentiation. To examine whether removal of SHP2 function during development disrupts progenitor cell proliferation, pregnant females were pulsed for 1 h with BrdU at two developmental time points (E12 and E16). No significant difference in the BrdU labeling index (number of BrdU-labeled nuclei/total nuclei per unit area of the proliferative zone) was observed between transgenic mice and wild-type littermates in the neocortical or striatal proliferative zones in the forebrain at either age ( Table 1) . These results suggest that removal of SHP2 does not affect cell cycle kinetics of neuroepithelial progenitor cells, at least in the neocortical and striatal primordia. To examine whether SHP2 removal disrupts progenitor cell migration, we compared cresyl violet or basic Fuchsin-stained sections of brains from E12, E17, and 2 month-old nestin-SHP2-CS mice and wild-type littermates. No differences in brain size, cortical thickness, lamination, or other histological features of the cerebral cortex, hippocampus, or cerebellum were observed between transgenic and wild-type mice (data not shown). We also stained sections of the brain from 2 month-old nestin-SHP2-CS and wild-type mice with antibodies to GFAP, nestin, and NeuN. Again, there was no difference in the pattern of staining for these markers (data not shown). These results indicate that in the nestin-SHP2-CS mice there are no obvious abnormalities in the histology of the brain during embryonic development or at maturity.
The nestin promoter-driven SHP2-CS transgene is induced within 6 h postcerebral ischemia
Induction of the endogenous nestin gene has been observed in neurons and reactive astrocytes after transient MCA occlusion-induced cerebral ischemia in rodents (33) (34) (35) . To examine induction of the nestin promoter-driven transgene after cerebral ischemia, nestin-SHP2-CS mice were subjected to transient MCA occlusion and processed 6 h later for X-gal staining. Expression was measured at this early postischemic phase because infiltration of reactive astrocytes, microglia, and proliferation of endothelial cells is minimal. The region affected by the transient ischemic involves the ventral and lateral cerebral cortex, neostriatum, and the amygdala. On the contralateral side some transgene expressing cells were present; however, on the ischemic side, there was a significant increase in the number and intensity of transgene expressing cells throughout the ischemic region. Induction of transgene expression was seen in the caudate putamen and outer layer of the piriform cortex and was especially evident in the amygdala (Fig. 5A-B) . Sections from this region were stained with X-gal and NeuN or GFAP antibodies to identify specific cell types that expressed the transgene (Fig. 5C-D) . Sections from the ischemic side showed a substantial decrease in NeuN immunoreactivity compared to the contralateral side, indicating that considerable neuronal death had occurred during this early postischemic phase. Some of the remaining NeuN-positive cells were costained with X-gal. Sections were not stained with GFAP antibody confirming reactive astrocytes were not present. These results indicate that during the early postischemic phase, transgene expression is induced in neurons and/or microglia within the infarct region.
Ischemic damage is increased in nestin-SHP2-CS mice
We have shown in previous studies that in the uninjured brain, low levels of SHP2 protein are detectable in a variety of neuronal cell types, including large motor neurons to smaller local circuit interneurons, but not in nonreactive glial cell types (17) ; however, SHP2 protein levels are strikingly increased in dying neurons and reactive astrocytes after focal cerebral ischemia (17) . Because transgene expression is also induced after cerebral ischemia in nestin-SHP2-CS mice, we used these animals to examine the affect the SHP2-CS dominant negative mutant has on ischemia-induced damage. To this end, focal ischemia was induced in the forebrain of nestin-SHP2-CS mice and nontransgenic littermates by transient MCA occlusion and infarct volume and a Labeling index (cells in S-phase) (%) ϭ (BrdU positive nuclei/ total nuclei) ϫ 100. For each animal the value is the mean of four sections.
infarct percentage were measured 6 days after reperfusion. We evaluated the consequences of nestin-SHP2-CS expression at this late postischemia time because it allows sufficient time for reactive gliosis to occur and therefore the potential impact the mutant has not only on neuronal survival signaling pathways but also the cellular response to the damage (i.e., reactive gliosis). Mice overexpressing the SHP2-CS mutant sustained larger infarction volumes than nontransgenic controls, 39.16 Ϯ 1.8 mm 3 (nϭ9) and 29.9 Ϯ 2.6 mm 3 (nϭ9), respectively (Fig. 6) . This result could not be attributed to enhanced tissue swelling in the mutant animals since the difference in the lesion size remained after a correction for edema (percentage of infarction: 28.0Ϯ2.9 in transgenic and 18.6Ϯ2.8 in wild-type mice, PϽ0.05). Laser Doppler flowmetry did not reveal a significant difference in the reduction of cortical blood flow after the occlusion of the middle cerebral artery in both mutant (22Ϯ6% of baseline, nϭ9) and wild-type (23Ϯ4% of baseline, nϭ9, PϾ0.05) mice. Moreover, the resting absolute cerebral blood flow did not significantly differ between the two groups [220 Ϯ 18 ml/100 g/min (nϭ6) and 220 Ϯ 17 ml/100 g/min (nϭ6) in transgenic and wild-type mice, respectively]. Last, carbon black perfusion (36) did not reveal any qualitative differences in the cerebrovascular anatomy, with respect to the circle of Willis and its major tributaries, between mutant and wild-type mice.
DISCUSSION
We have shown previously that SHP2 immunoreactivity is detectable in neuroepithelium-derived progenitor cells (17) . Cell culture studies have indicated that these nervous system progenitor cells require mitogens that include bFGF and EGF for renewal and lineage restriction, and neurotrophic factors such as CNTF for differentiation (37) . Significantly, an ample body of evidence based on cell culture data has indicated that SHP2 has a critical role in cell signaling pathways initiated by these growth and differentiation factors (38, 39) . Thus, a priori, it would be expected that removal of endogenous SHP2 function in nervous system progenitor cells would affect nervous system development. However, nestin-SHP2-CS transgenic mice are viable, appear to develop normally, and do not show any obvious histological abnormalities in the embryonic and adult brain. One explanation for these results could be that SHP2 function is redundant during development of the nervous system. The distribution and function of the related protein tyrosine phosphatase SHP1 (reviewed in refs 38, 39) has not been extensively examined in the nervous system in this regard. Alternatively, the level of expression of the SHP2-CS mutant in the progenitor cells of the developing neuroepithelium may not be high enough to attenuate endogenous SHP2 activity.
In contrast to the lack of an obvious developmental defect in nestin-SHP2-CS animals, the neuronal response to ischemic injury was clearly compromised in Figure 5 . X-gal staining and immunohistochemistry in brain sections 6 h after reperfusion. Adult nestin-SHP2-CS mice were subjected to transient focal cerebral ischemia by MCA occlusion. Six hours after reperfusion, sections from the contralateral and ipsilateral hemispheres were stained with X-gal. On the contralateral side, some X-gal-stained cells were seen within the amygdala and piriform cortex (A). However, a dramatic increase in the number and intensity of X-galstained cells was seen on the ipsilateral side (B). Sections from the contralateral (C) and ipsilateral hemispheres (D) costained with X-gal and NeuN antibody. the transgenic mice. This was evident in the MCA occlusion experiments, where the ischemia-induced infarct size in nestin-SHP2-CS mice was 34% larger than that observed in wild-type littermates. Significant differences in physiological parameters, such as MABP, arterial blood gases and rectal temperature, were not observed between nestin-SHP2-CS and wild-type mice (data not shown). Moreover, transgenic mice did not differ from wild-type littermates hemodynamically or in their cerebrovascular anatomy, indicating that the enhanced severity of the ischemic outcome in the mutants was a result of the overexpression of the dominant negative form of SHP2. These results indicate that SHP2 is a crucial component in cell signaling important in neuroprotection during ischemia. Several studies have shown that ischemic damage leads to differential regulation of mRNAs or proteins for neurotrophic factors and growth factors; for example, induction of NGF and BDNF (40, 41) ; bFGF (42) (43) (44) , IGF (40) , TGF␣ (45) , CNTF (46) and reduction of NT-3 (41, 47) . Furthermore, intraventricular injection of BDNF (48), IGF-1 (49, 50) , bFGF (51) , and NT-4/6 (52) or overexpression of NGF in transgenic mice (53) results in a reduced infarct size after cerebral ischemia. These results indicate that a number of neurotrophic and mitogenic growth factors can provide neuroprotection after cerebral ischemia, raising the possibility that SHP2 may have a role in one or more of the signaling cascades activated by these factors (17, 38, 39) .
Although our studies demonstrate that SHP2 is important for preventing or limiting the amount of cell death that occurs after ischemia-induced brain damage, it still remains to be determined whether the increased sensitivity to cell death in nestin-SHP2-CS animals is due to a defect in a survival pathway in the hypoxic neurons or to a defect in a protective cellular response to the damage. Both possibilities should be considered either separately or jointly, and studies are under way to elaborate on this. Indeed, preliminary experiments with neuronal cultures derived from wild-type or nestin-SHP2-CS animals indicate that SHP2-CS mutant neurons display an increased sensitivity to hypoxia-induced apoptotic death.
